Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.
Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, Roberts CC, Lickliter J, Krishnarajah J, Bett A, Dubey S, Finn T, Coller BA. Manoff SB, et al. Among authors: lickliter j. Hum Vaccin Immunother. 2019;15(9):2195-2204. doi: 10.1080/21645515.2018.1546523. Epub 2019 Jun 3. Hum Vaccin Immunother. 2019. PMID: 30427741 Free PMC article. Clinical Trial.
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB, Van Damme P, Withanage K, Fissette LA, David MP, Maleux K, Schmidt AC, Picciolato M, Dieussaert I. Beran J, et al. Among authors: lickliter jd. J Infect Dis. 2018 Apr 23;217(10):1616-1625. doi: 10.1093/infdis/jiy065. J Infect Dis. 2018. PMID: 29401325 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH, Witham K, Depelsenaire ACI, Veitch M, Wells JW, Wheatley A, Pryor M, Lickliter JD, Francis B, Rockman S, Bodle J, Treasure P, Hickling J, Fernando GJP. Forster AH, et al. Among authors: lickliter jd. PLoS Med. 2020 Mar 17;17(3):e1003024. doi: 10.1371/journal.pmed.1003024. eCollection 2020 Mar. PLoS Med. 2020. PMID: 32181756 Free PMC article. Clinical Trial.
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Keech C, et al. Among authors: lickliter jd. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2. N Engl J Med. 2020. PMID: 32877576 Free PMC article. Clinical Trial.
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Khoo JK, Montgomery AB, Otto KL, Surber M, Faggian J, Lickliter JD, Glaspole I. Khoo JK, et al. Among authors: lickliter jd. J Aerosol Med Pulm Drug Deliv. 2020 Feb;33(1):15-20. doi: 10.1089/jamp.2018.1507. Epub 2019 Jan 30. J Aerosol Med Pulm Drug Deliv. 2020. PMID: 30698487 Free PMC article. Clinical Trial.
Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial.
Depelsenaire ACI, Witham K, Veitch M, Wells JW, Anderson CD, Lickliter JD, Rockman S, Bodle J, Treasure P, Hickling J, Fernando GJP, Forster AH. Depelsenaire ACI, et al. Among authors: lickliter jd. PLoS One. 2021 Jul 30;16(7):e0255282. doi: 10.1371/journal.pone.0255282. eCollection 2021. PLoS One. 2021. PMID: 34329337 Free PMC article. Clinical Trial.
STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects.
Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. Shrewsbury SB, et al. Among authors: lickliter j. Headache. 2019 Mar;59(3):394-409. doi: 10.1111/head.13476. Epub 2019 Jan 19. Headache. 2019. PMID: 30659611 Clinical Trial.
64 results